[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Jung SH, Kim HC, Yu CS, Kim JC: Solitary preleukemic granulocytic sarcoma as a cause of small bowel obstruction. Gut Liver; 2007 Jun;1(1):82-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary preleukemic granulocytic sarcoma as a cause of small bowel obstruction.
  • Granulocytic sarcoma is an extramedullary tumor composed of immature granulocytic cells.
  • We report a case of a 48-year-old man presenting with symptoms of small bowel obstruction.
  • The findings were consistent with the diagnostic findings of solitary granulocytic sarcoma (preleukemic).
  • Sequentially, the patient developed FAB M2 acute myeloid leukemia.
  • Induction chemotherapy including cytarabine and idarubicine was done which led to complete remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Dec 25;90(6):364-72 [11156520.001]
  • [Cites] Hong Kong Med J. 2005 Jun;11(3):204-6 [15951586.001]
  • [Cites] Acta Chir Belg. 1999 Apr;99(2):78-81 [10352737.001]
  • [Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12):2586-8 [9860434.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Cancer. 1973 Jun;31(6):1315-27 [4513690.001]
  • [Cites] Cancer. 1975 May;35(5):1333-40 [1054617.001]
  • [Cites] Acta Cytol. 2004 Sep-Oct;48(5):641-4 [15471256.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1100-3 [12764375.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • (PMID = 20485664.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871656
  • [Keywords] NOTNLM ; Acute myeloid leukemia / Granulocytic sarcoma / Small bowel obstruction
  •  go-up   go-down


2. Dickson MA, Shah MA, Rathkopf D, Tse A, Carvajal RD, Wu N, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK: A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol; 2010 Nov;66(6):1113-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical activity included 2 partial responses in small bowel cancer and bladder cancer and 1 complete response in mucosal melanoma.
  • Clinical benefit was correlated with the presence of wild-type p53.
  • CONCLUSIONS: Treatment with flavopiridol and FOLFIRI is a safe and effective regimen.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2637-45 [18981292.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2527-36 [11489836.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4209-19 [11751522.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):549-55 [12813134.001]
  • [Cites] Semin Radiat Oncol. 2003 Jul;13(3):176-81 [12903007.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):315-22 [15122079.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 15;201(2):589-95 [8002990.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2973-8 [8674031.001]
  • [Cites] Curr Opin Genet Dev. 1996 Feb;6(1):56-64 [8791491.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1876-83 [10430095.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):889-98 [15681535.001]
  • [Cites] Contemp Clin Trials. 2005 Apr;26(2):131-40 [15837436.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3836-45 [15897584.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):249-53 [15978659.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5935-41 [16115936.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Haematologica. 2006 Mar;91(3):390-3 [16503551.001]
  • [Cites] Invest New Drugs. 2006 Jul;24(4):305-10 [16683073.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1158-65 [16600980.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5841-6 [17908977.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2312-20 [18381438.001]
  • [Cites] Clin Lung Cancer. 2008 May;9(3):160-5 [18621626.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2168-81 [11489790.001]
  • (PMID = 20953860.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA067819; United States / NCI NIH HHS / CA / R01CA67819
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 0 / Protein Kinase Inhibitors; 45AD6X575G / alvocidib; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS195344; NLM/ PMC2957673
  •  go-up   go-down


3. Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, Smith D, Glatstein E, Fraker DL, Busch TM: Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res; 2006 Sep 15;12(18):5464-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.
  • PURPOSE: A phase II trial of Photofrin-mediated i.p. photodynamic therapy shown in a previous report limited efficacy and significant acute, but not chronic, toxicity.
  • A secondary aim of this trial and the subject of this report is to determine Photofrin uptake in tumor and normal tissues.
  • Photofrin uptake was measured by spectroflurometric analysis of drug extracted from tumor and normal tissues removed at surgery.
  • Differences in drug uptake among these tissues were statistically considered using mixed-effects models.
  • In normal tissues, drug uptake significantly (P<0.0001) differed as a function of seven different tissue types.
  • In the toxicity-limiting tissue of intestine, the model-based mean (SE) Photofrin level was 2.70 ng/mg (0.32 ng/mg) and 3.42 ng/mg (0.24 ng/mg) in full-thickness large and small intestine, respectively.
  • In tumors, drug uptake significantly (P=0.0015) differed as a function of patient cohort: model-based mean Photofrin level was 3.32 to 5.31 ng/mg among patients with ovarian, gastric, or small bowel cancer; 2.09 to 2.45 ng/mg among patients with sarcoma and appendiceal or colon cancer; and 0.93 ng/mg in patients with pseudomyxoma.
  • Ovarian, gastric, and small bowel cancers showed significantly higher Photofrin uptake than full-thickness large and/or small intestine.
  • However, the ratio of mean drug level in tumor versus intestine was modest (<or=2.31).
  • CONCLUSIONS: Some selectivity is found in Photofrin uptake between tumor and normal tissues of the peritoneal cavity, but absolute differences in drug uptake relative to toxicity-limiting normal tissues (intestine) are small.
  • This narrow differential in drug selectivity likely contributes to a narrow window in therapeutic application, which has been previously reported.
  • [MeSH-minor] Biopsy. Cohort Studies. Female. Gastrointestinal Neoplasms / drug therapy. Humans. Injections, Intraperitoneal. Models, Biological. Organ Specificity. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000681.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA-87971; United States / NCI NIH HHS / CA / R01 CA-85831
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


Advertisement
4. Kitagawa Y, Sameshima Y, Shiozaki H, Ogawa S, Masuda A, Mori S, Teramura M, Masuda M, Kameoka S, Motoji T: Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation. Int J Hematol; 2008 May;87(4):410-3
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation.
  • Isolated primary granulocytic sarcoma is a rare disease that presents as an extramedullary tumor of myeloid lineage cells.
  • Herein, we report the case of a 33-year-old woman with a primary isolated granulocytic sarcoma which originated in the small intestine.
  • After she recovered from surgery, she received intensive chemotherapy equivalent to that for AML, followed by allogeneic bone marrow transplantation from an HLA-matched, unrelated donor.
  • This case illustrates the effectiveness of our therapeutic strategy for isolated granulocytic sarcoma, not only with surgical resection of the tumor and intensive chemotherapy equivalent to that for AML, but also with allogeneic bone marrow transplantation, performed while no sign of AML is observed.
  • [MeSH-major] Bone Marrow Transplantation. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology. Sarcoma, Myeloid / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Female. Humans

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365139.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Olnes MJ, Nicol T, Duncan M, Bohlman M, Erlich R: Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy. Leuk Lymphoma; 2002 Apr;43(4):817-21
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.
  • Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature.
  • Patients with this malignancy have been treated with chemotherapy regimens used against non-Hodgkin's lymphomas.
  • Staging of the tumor with CT scan, PET scan, and bone marrow biopsy demonstrated inguinal and abdominal lymphadenopathies, a large mass encasing the small bowel, and extensive liver infiltration.
  • Morphologic and cytochemical analysis of biopsies from the abdominal mass and inguinal node were consistent with a diagnosis of IDCS, and immunohistochemical stains of the lymph node were positive for CLA, Kp-1, S-100, while negative for CD1a, CD3, CD20, CKER, and HMB45.
  • Treatment of this patient with ABVD chemotherapy resulted in rapid clinical improvement with a marked decrease in tumor burden after two cycles of ABVD, and a complete response after six cycles of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells / pathology. Sarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153170.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


6. Xavier SG, Fagundes EM, Hassan R, Bacchi C, Conchon M, Tabak DG, Spector N, Zalcberg IR: Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature. Leuk Res; 2003 Nov;27(11):1063-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the small intestine with CBFbeta/MYH11 fusion gene: report of an aleukaemic case and review of the literature.
  • The possibility of an association between the development of granulocytic sarcoma of the small intestine (GSSI) and the M4Eo subtype of AML was suggested in nine previous case reports.
  • Here we report an aleukaemic case of GSSI with inv(16) and its molecular equivalent, the CBFbeta/MYH11 fusion gene, detected by reverse transcriptase-polymerase chain reaction (RT-PCR), that after treatment with conventional AML chemotherapy followed by autologous bone marrow transplantation, achieved complete haematological and molecular remission on bone marrow examination.
  • After chemotherapy, a thickened ileum wall positive for CBFbeta/MYH11 on tumour mass samples was still observed on computed tomography (CT) studies, raising the question of residual GS representing a reservoir of malignant cells.
  • This case demonstrates the critical need of multidisciplinary diagnosis and follow-up of this entity combining immunopathologic, cytogenetic and molecular studies, reinforcing the potentiality of risk-adapted therapy strategies, as it is increasingly claimed for patients with overt AML.
  • [MeSH-major] Intestinal Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Sarcoma, Myeloid / genetics
  • [MeSH-minor] Adult. Humans. Ileum / radiography. Leukemia / complications. Male. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859999.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 24
  •  go-up   go-down


7. Lee SY, Park SJ, Kim YH, Lee JH: Nonleukemic granulocytic sarcoma presenting as intussusception of small bowel. Int J Clin Oncol; 2008 Oct;13(5):467-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonleukemic granulocytic sarcoma presenting as intussusception of small bowel.
  • Granulocytic sarcoma (GS) is defined as a localized tumor mass composed of myeloid blasts and/or immature myeloid cells in an extramedullary site.
  • In rare cases, it occurs as a "preleukemic" condition and may precede the onset of AML, which occurs within several months if the patient is not treated with AML-type systemic chemotherapy.
  • Recently, we discovered one case of nonleukemic GS in the small intestine incidentally when intussusception was suspected.
  • The patient visited the emergency department, in October 2006, with symptoms of small-bowel obstruction.
  • Intussusception due to a small-intestinal mass was suspected after evaluation, and small-intestine segmental resection was performed.
  • The patient received three cycles of chemotherapy, applied as for AML (cytosine arabinoside and anthracycline), and is currently, as of October 29, 2007, showing no other marked indisposition; he has been disease-free for 12 months.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small. Intussusception / diagnosis. Sarcoma, Myeloid / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Cancer. 1986 Dec 15;58(12):2697-709 [3465429.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1570-4 [17090205.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):912-7 [2423654.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):745-8 [16891824.001]
  • (PMID = 18946761.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Rénard C, Girard S, Pracros JP, Dijoud F, André JM, Mialou V, Bertrand Y: [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases]. Arch Pediatr; 2010 Feb;17(2):149-53
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulocytic sarcoma, a diagnostic challenge: 3 pediatric cases].
  • Granulocytic sarcoma (GS) is a rare extramedullary tumor frequently associated with acute myeloblastic leukemia (AML).
  • We report 3 cases of pediatric granulocytic sarcomas with various locations: skin, orbit, and bowel.
  • In all 3 cases, the diagnosis was delayed or initially missed.
  • GS is treated with chemotherapy, like AML.
  • [MeSH-major] Facial Neoplasms / diagnosis. Intestinal Neoplasms / diagnosis. Intestine, Small. Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Orbital Neoplasms / diagnosis. Sarcoma, Myeloid / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy. Bone Marrow / pathology. Bone Marrow Transplantation. Child, Preschool. Combined Modality Therapy. Diagnostic Errors. Female. Follow-Up Studies. Humans. Infant. Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / drug therapy. Leukemia, Biphenotypic, Acute / pathology. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19945260.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Svrcek M, Tiret E, Bennis M, Guyot P, Fléjou JF: KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case. Dis Colon Rectum; 2009 Jan;52(1):154-8
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case.
  • Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), has been identified in all four forms of Kaposi's sarcoma (classic, endemic, HIV-associated and iatrogenic).
  • We report the rare case of an intestinal (small intestine and rectosigmoid) Kaposi's sarcoma in a 62-year-old HIV-negative man with ulcerative colitis.
  • This patient was receiving immunosuppressive therapy with steroids and azathioprine.
  • To date, the causative role of KSHV/HHV8 in the pathophysiology of Kaposi's sarcoma associated with ulcerative colitis has only been proven for cutaneous lesions but not for intestinal lesions of Kaposi's sarcoma.
  • We report for the first time, the expression of HHV8 (by using immunohistochemistry) in colonic Kaposi's sarcoma in a patient with an ulcerative colitis-related tumor.
  • At laparotomy, numerous Kaposi's sarcoma lesions were found in the small intestine, which were left in situ.
  • Forty months after surgery and following withdrawal of immunosuppressive therapy, the patient had no evidence of any disease and a normal abdominal and thoracic CT scan.
  • Cases of colorectal Kaposi's sarcoma complicating inflammatory bowel disease should be managed with a conservative approach and discontinuation of the immunosuppressive treatment.
  • However, discontinuation of the immunosuppression is not always possible and in those cases chemotherapy may be indicated.
  • [MeSH-major] Colitis, Ulcerative / drug therapy. Colorectal Neoplasms / complications. Herpesvirus 8, Human. Immunosuppressive Agents / therapeutic use. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / virology

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273971.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


10. Talamonti MS, Goetz LH, Rao S, Joehl RJ: Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg; 2002 May;137(5):564-70; discussion 570-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management.
  • HYPOTHESIS: This study was done to review the clinical presentation, surgical management, pathologic features, and prognostic factors for primary small-bowel cancers.
  • The distribution of tumors by histological features was as follows: adenocarcinoma (33%), carcinoid tumor (29%), lymphoma (19%), and sarcoma (19%).
  • Cumulative 5-year survival rate was 37% in the adenocarcinoma group, 64% in the carcinoid tumor group, 29% in the lymphoma group, and 22% in the sarcoma group.
  • Patient age, tumor location, histological grade, and use of chemotherapy and radiation therapy did not significantly influence survival.
  • The median time to recurrence was 16 months.
  • Twenty-one patients (16%) developed associated primary cancers.
  • [MeSH-major] Intestinal Neoplasms / mortality. Intestinal Neoplasms / surgery
  • [MeSH-minor] Actuarial Analysis. Adenocarcinoma / mortality. Adenocarcinoma / surgery. Carcinoid Tumor / mortality. Carcinoid Tumor / surgery. Female. Humans. Intestine, Small. Lymphoma / mortality. Lymphoma / surgery. Male. Middle Aged. Prognosis. Retrospective Studies. Sarcoma / mortality. Sarcoma / surgery. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11982470.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Wheeler DW, Baigrie RJ: Palliative surgery for acute bowel obstruction caused by Kaposi's sarcoma in a patient with AIDS. Int J Clin Pract; 2003 May;57(4):347-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative surgery for acute bowel obstruction caused by Kaposi's sarcoma in a patient with AIDS.
  • We report a 39-year-old man who developed intermittent nausea and vomiting, which was originally thought to be a side-effect of the chemotherapy he was receiving for facial Kaposi's sarcoma.
  • However, he was found to have intraperitoneal Kaposi's sarcoma causing small bowel obstruction, which was successfully excised at laparotomy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Ileal Neoplasms / complications. Intestinal Obstruction / etiology. Sarcoma, Kaposi / complications


12. Goodman KA, Wolden SL, LaQuaglia MP, Alektiar K, D'Souza D, Zelefsky MJ: Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience. Brachytherapy; 2003;2(3):139-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The IOHDR dose was prescribed to a depth of 0.5 cm from the surface of a multichannel tissue-equivalent applicator.
  • The median prescription dose was 12 Gy (range, 4-15 Gy).
  • Late events that occurred in or near the IOHDR treatment site included small bowel obstruction, broncho-esophageal fistula, and bone growth retardation.
  • CONCLUSIONS: IOHDR is emerging as an integral part of multimodality therapy for pediatric solid tumors as an adjunct to EBRT for local control.
  • Subacute toxicities occurred rarely and may be related to the combination of extensive surgery, EBRT, and multi-agent chemotherapy in this population.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Intraoperative Period. Male. Morbidity. Radiotherapy Dosage. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / radiotherapy. Sarcoma / surgery. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15062136.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Steinert DM, Blakely LJ, Patel SR, Burgess MA, Chen LL, Trent JC, Raymond AK, Benjamin RS: Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):9047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of gastrointestinal stromal tumors (GIST) and other intra-abdominal sarcomas (IAS) in the era of imatinib therapy.
  • In the era of kit immunohistochemistry and imatinib mesylate therapy the outcome of IASs is unknown.
  • METHODS: We analyzed 268 consecutive patients who were referred to our institution for evaluation of the diagnosis of GIST from 12/15/00 to 9/1/01.
  • Patients diagnosed with GIST were treated with imatinib mesylate, and patients diagnosed with other IAS were treated with standard sarcoma chemotherapy.
  • A single sarcoma pathologist reviewed all patients' tumor blocks.
  • RESULTS: Of 268 patients, 4 patients were excluded because of diagnoses other than sarcoma.
  • Another 46 patients were excluded because no data were available at the time of this abstract.
  • Of the remaining 218 patients, 159 (72.9%) were GIST and 59 (27.1%) were IAS specifically: 31 leiomyosarcoma, 10 spindle cell tumors, 4 unclassified sarcomas, and 14 other types of sarcoma.
  • The most common primary tumor sites for patients with GIST were stomach (37.1%), small bowel (34%), and colon (6.3%); whereas, patients with other intra-abdominal sarcomas occurred in the retroperitoneum (25.4%), abdominal viscera (18.6%), and pelvis (11.9%).
  • While median survival from the time of diagnosis has not been reached in patients with GIST, in other IAS median survival is 63.8 months.
  • Time to progression in patients with GIST was 16.4 months after imatinib and 5.1 months in patients with IAS treated with standard sarcoma chemotherapy.
  • CONCLUSIONS: Survival and time to progression are worse for IAS compared to GISTs.
  • New therapies for these tumors are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Frequently this includes adjacent organs such as colon, small bowel, kidney, adrenal, and pancreas.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


15. Bölling T, Schuck A, Pape H, Rübe C, Meyer FM, Martini C, Timmermann B, Asadpour B, Kortmann RD, Beck JD, Langer T, Paulides M, Könemann S, Willich N: [Register for the evaluation of side effects after radiation in childhood and adolescence--first results]. Klin Padiatr; 2007 May-Jun;219(3):139-45
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Late effects after radiotherapy in childhood and adolescence have mainly been characterized retrospectively with small patient numbers.
  • Documentation is planned for all children who receive radiotherapy in one of the German pediatric therapy trials.
  • Side effects mainly concerned joints with functional impairment (after combined radiotherapy and surgery), the bowel, skin and subcutis as well as blood parameters under continued chemotherapy.
  • Patients with late side effects of a higher grade were mainly treated for Ewing's or soft tissue sarcomas (n=235 patients), representing 33.8% of all patients in this study.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Prospective Studies. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retreatment. Retrospective Studies. Risk Factors. Sarcoma / drug therapy. Sarcoma / radiotherapy. Sarcoma / surgery. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / surgery

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525907.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


16. Dusenbery KE, Potish RA, Argenta PA, Judson PL: On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol; 2005 Jun;28(3):295-300
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective report analyzes patterns of failure, survival, and toxicity in 42 women with stage I and 7 patients with stage II uterine sarcomas treated from 1972 through 1998 to identify patients likely to benefit from pelvic or abdominal radiotherapy and chemotherapy.
  • Four of these patients also received adjuvant chemotherapy.
  • Acute toxicity was acceptable as measured by a median 1-kg weight loss from radiotherapy and a 2% rate of failure to complete therapy.
  • Chronic toxicity consisted of 3 small bowel obstructions and 1 sigmoid colon obstruction.
  • Although the frequent occurrence of peritoneal failures suggests a role for prophylactic abdominal radiation for mixed mullerian tumors, more effective systemic therapy is necessary to substantially increase the chance of cure for women with early-stage uterine sarcomas.
  • [MeSH-major] Sarcoma / radiotherapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / prevention & control. Abdominal Neoplasms / secondary. Antineoplastic Agents / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Dactinomycin / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Hysterectomy / methods. Ifosfamide / therapeutic use. Intestinal Obstruction / etiology. Leiomyosarcoma / mortality. Leiomyosarcoma / radiotherapy. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Life Tables. Mixed Tumor, Mullerian / mortality. Mixed Tumor, Mullerian / radiotherapy. Mixed Tumor, Mullerian / secondary. Mixed Tumor, Mullerian / surgery. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / prevention & control. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. Radiation Injuries / etiology. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923804.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 1CC1JFE158 / Dactinomycin; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 18
  •  go-up   go-down


17. Morandi X, Riffaud L, Haegelen C, Lancien G, Kerbrat P, Guegan Y: [Extraosseous Ewing's sarcoma of the spinal epidural space]. Neurochirurgie; 2001 Feb;47(1):38-44
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extraosseous Ewing's sarcoma of the spinal epidural space].
  • Ewing's sarcoma is found exceptionally as a primary epidural tumor of the spine.
  • Four cases of extraosseous Ewing's sarcoma of the spinal epidural space are presented.
  • Symptoms included back pain and/or radicular pain, paresis of one or more limbs, sensory disturbances, and bladder and bowel dysfunction.
  • Most patients received radiation therapy and chemotherapy.
  • Twelve patients died, 1 to 54 months (mean, 18) after diagnosis.
  • Even though the number of patients was too small in this series for statistical analysis, partially resected tumors do appear to be associated with a higher mortality.
  • [MeSH-major] Epidural Neoplasms / surgery. Sarcoma, Ewing / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Magnetic Resonance Imaging. Male. Prognosis. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11283454.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Delacruz V, Takahashi H, Nishida S, Tzakis A, Ruiz P: Segmental xanthomatosis of the small intestine. A case report and review of the literature. Hum Pathol; 2009 Jan;40(1):139-42
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Segmental xanthomatosis of the small intestine. A case report and review of the literature.
  • Intestinal xanthomatosis is a rare, nonneoplastic lesion that may involve the small bowel in a localized or generalized way.
  • It may be a cause of clinically significant obstruction and should be included in the differential diagnosis with other causes of bowel obstruction, particularly in patients with history of radiation therapy or chemotherapy.
  • The patient was a 22-year-old man who developed intestinal obstruction 16 years after radiation therapy for Ewing sarcoma of the right hip.
  • [MeSH-major] Ileum / pathology. Intestinal Obstruction / etiology. Intestinal Obstruction / pathology. Intestine, Small / pathology. Xanthomatosis / complications
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Radiotherapy / adverse effects. Sarcoma, Ewing / radiotherapy. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2009 Jul;40(7):1052; author reply 1052 [19342078.001]
  • (PMID = 18755495.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 8
  •  go-up   go-down


19. Palanivelu C, Rangarajan M, Senthilkumar R, Annapoorni S: Laparoscopic management of an obstructing granulocytic sarcoma of the jejunum causing intussusception in a nonleukemic patient: report of a case. Surg Today; 2009;39(7):606-9
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of an obstructing granulocytic sarcoma of the jejunum causing intussusception in a nonleukemic patient: report of a case.
  • Granulocytic sarcoma is an extramedullary tumor of immature myeloid cells which is often a forerunner to the development of acute myelogenous leukemia.
  • Granulocytic sarcoma of the gastrointestinal tract frequently involves the small intestine and often presents with abdominal pain and obstruction.
  • This type of manifestation has never before been reported.
  • The initial pathological findings were high-grade non-Hodgkin's lymphoma; immunohistochemistry confirmed a diagnosis of granulocytic sarcoma.
  • Chemotherapy is the treatment of choice and surgery is indicated only in the event of complications, such as bowel obstruction, bleeding, or perforation.
  • The prognosis of granulocytic sarcoma is similar to that of myeloid leukemia.
  • [MeSH-major] Intussusception / surgery. Jejunal Neoplasms / surgery. Sarcoma, Myeloid / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):865-6 [10690184.001]
  • [Cites] J Am Acad Dermatol. 1997 Aug;37(2 Pt 2):308-11 [9270534.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Ann Intern Med. 1995 Sep 1;123(5):351-3 [7625623.001]
  • [Cites] J Nippon Med Sch. 2000 Oct;67(5):392-5 [11031375.001]
  • [Cites] Med Clin (Barc). 1995 Mar 18;104(10):377-80 [7707732.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12 ):2586-8 [9860434.001]
  • [Cites] Chirurg. 2002 Nov;73(11):1127-31 [12430065.001]
  • [Cites] Gastroenterology. 1991 Feb;100(2):555-9 [1985052.001]
  • [Cites] Hong Kong Med J. 2005 Jun;11(3):204-6 [15951586.001]
  • [Cites] J Fla Med Assoc. 1997 Feb;84(2):111-4 [9066237.001]
  • [Cites] World J Surg. 2000 Apr;24(4):421-9 [10706914.001]
  • [Cites] Am Surg. 2001 Aug;67(8):764-6 [11510579.001]
  • [Cites] Gastroenterol Hepatol. 2003 Jun-Jul;26(6):347-50 [12809571.001]
  • (PMID = 19562450.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Pawlik TM, Vauthey JN, Abdalla EK, Pollock RE, Ellis LM, Curley SA: Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg; 2006 Jun;141(6):537-43; discussion 543-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver.
  • HYPOTHESIS: A subset of patients with sarcoma liver metastasis may benefit from hepatic resection and/or ablation.
  • PATIENTS AND METHODS: Sixty-six patients who underwent hepatic resection and/or open radiofrequency ablation of metastatic sarcoma between July 1, 1996, and April 30, 2005, were identified from the database.
  • RESULTS: The primary sarcoma site was the abdomen or retroperitoneum (n = 22), stomach (n = 18), small or large bowel (n = 17), pelvis (n = 4), uterus (n = 3), or other (n = 2).
  • Tumor pathologic types included gastrointestinal stromal tumor (n = 36), leiomyosarcoma (n = 18), and sarcoma not otherwise classified (n = 12).
  • Treatment with radiofrequency ablation (either alone or combined with resection) (P = .002) and lack of adjuvant chemotherapy (P = .01) predicted shorter disease-free survival.
  • CONCLUSIONS: Long-term survival can be achieved following surgical treatment of sarcoma liver metastasis, especially in patients with gastrointestinal stromal tumor.
  • Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival.
  • [MeSH-major] Catheter Ablation. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Neoplasms / pathology. Disease-Free Survival. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Retroperitoneal Neoplasms / pathology. Retrospective Studies. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785353.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


21. Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J: Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. Oncology; 2005;69(4):326-32
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
  • The aim of this analysis was to report on our experience of the utility of coincidence positron emission tomography (co-PET) based on an 18F-FDG gamma camera in assessing treatment response to imatinib using CT as the comparator and the final clinical outcome as the end point.
  • All patients had biopsy-proven malignant GIST and were on treatment with the targeted pharmacotherapeutic agent imatinib.
  • The majority of the patients were receiving treatment as part of the randomized trial of the European Organization for Research and Treatment of Cancer, the Australian Gastrointestinal Trials Group and the Italian Sarcoma Group, comparing 400 with 800 mg (400 mg b.i.d.).
  • There were 10 primary lesions (4 stomach, 4 duodenal, 2 small bowel), 9 of which were demonstrated on initial 18F-FDG co-PET examinations (90%).
  • CONCLUSION: 18F-FDG co-PET is a useful modality to monitor treatment response to imatinib in patients with malignant GIST.
  • Although there is a relatively reduced sensitivity when compared with CT for the detection of lesions especially in the liver, co-PET changes in several instances precede the changes on CT scanning.
  • This modality has the potential to influence clinical decision making and should be considered as part of the standard care of patients on imatinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorodeoxyglucose F18. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / pathology. Piperazines / therapeutic use. Positron-Emission Tomography. Pyrimidines / therapeutic use. Tomography, X-Ray Computed
  • [MeSH-minor] Benzamides. Gamma Cameras. Humans. Imatinib Mesylate. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16293972.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


22. Boehm R, Till H, Landes J, Schmid I, Joppich I: Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report. Eur J Pediatr Surg; 2003 Aug;13(4):272-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report.
  • In older patients and adolescents, the diagnosis can be complicated due to the lower incidence and variable subacute symptoms.
  • External diagnostics showed no pathological signs or were misinterpreted as a malfunction of intestinal motility.
  • An ileoilealic intussusception was found, caused by a small bowel tumour, which almost completely obstructed the intestinal lumen.
  • It was resected and bowel continuity was re-established.
  • Histopathology revealed a very rare, highly malignant mesenchymal Ewing sarcoma, infiltrating the complete bowel wall.
  • After the postoperative course, the patient was transferred to our oncological department for chemotherapy.
  • In older children or young adults, intestinal malignancies are extremely rare.
  • Nevertheless, if these patients suffer from unspecific complaints of chronic intestinal obstruction, a tumour must be ruled out.
  • A Ewing sarcoma may be responsible for an intussusception.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / therapy. Ileal Diseases. Ileal Neoplasms / therapy. Intussusception / surgery. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Cisplatin / administration & dosage. Combined Modality Therapy. Digestive System Surgical Procedures / methods. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Stem Cell Transplantation. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13680499.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


23. Pestieau SR, Jelinek JS, Chang D, Jacquet P, Sugarbaker PH: CT in the selection of patients with abdominal or pelvic sarcoma for reoperative surgery. J Am Coll Surg; 2000 Jun;190(6):700-10
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT in the selection of patients with abdominal or pelvic sarcoma for reoperative surgery.
  • BACKGROUND: Retroperitoneal or visceral sarcoma may recur with disease limited to the abdomen and pelvis.
  • In this clinical situation, further surgical treatments in an attempt to control the disease may be appropriate.
  • STUDY DESIGN: Preoperative abdominal and pelvic CT scans of 33 patients with recurrent sarcoma were reviewed retrospectively.
  • All patients underwent reoperative surgery and, when appropriate, perioperative intraperitoneal chemotherapy.
  • These findings included tumor in the left lower quadrant (p = 0.032), tumor in the pelvis (p = 0.008), and tumor in the distal jejunum (p = 0.032).
  • A statistical approach using a tree-structured diagram showed that patients with tumor diameter greater than 5 cm in the pelvis accompanied by tumor involvement of more than one segment of small bowel had a 0% probability of postoperative disease-free survival.
  • CONCLUSIONS: For patients with recurrent sarcoma, selection criteria were generated by a preoperative CT of the abdomen and pelvis.
  • [MeSH-major] Abdominal Neoplasms / radiography. Abdominal Neoplasms / surgery. Patient Selection. Pelvic Neoplasms / radiography. Pelvic Neoplasms / surgery. Sarcoma / radiography. Sarcoma / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10873006.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


24. Bauer TW, Hahn SM, Spitz FR, Kachur A, Glatstein E, Fraker DL: Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis. Ann Surg Oncol; 2001 Apr;8(3):254-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis.
  • INTRODUCTION: Sarcomatosis is the disseminated intraperitoneal spread of sarcoma.
  • It is a condition for which there is no effective treatment.
  • Photodynamic therapy (PDT) is a cancer treatment modality that uses a photosensitizing agent and laser light to kill cells.
  • We report our preliminary Phase II clinical trial experience using PDT for the treatment of intraperitoneal sarcomatosis.
  • METHODS: From May 1997 to December 1998 eleven patients received twelve PDT treatments for intraperitoneal sarcomatosis.
  • Light therapy was administered at a fluence of 2.5 J/cm2 of 532 nm green light to the mesentery and serosa of the small bowel and colon; 5 J/cm2 of 630 nm red light to the stomach and duodenum; 7.5 J/cm2 of red light to the surface of the liver, spleen, and diaphragms; and 10 J/cm2 of red light to the retroperitoneal gutters and pelvis.
  • Response to treatment was evaluated by abdominal CT scan at 3 and 6 months, diagnostic laparoscopy at 3 to 6 months, and clinical examination every 3 months.
  • RESULTS: Adequate tumor debulking required an omentectomy in eight patients (73%), small bowel resection in seven patients (64%), colon resection in four patients (36%), splenectomy in one patient (9%), and a left spermatic cord resection in one patient.
  • [MeSH-major] Hematoporphyrin Photoradiation / methods. Peritoneal Neoplasms / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dihematoporphyrin Ether / adverse effects. Dihematoporphyrin Ether / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Laparotomy. Male. Middle Aged. Pennsylvania / epidemiology. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314943.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


25. Lee KH, Fiedler P, Passarelli J, Bobrow S: Autoimmune hemolytic anemia associated with postirradiation malignant stromal tumor (leiomyosarcoma) of the jejunum. Ann Diagn Pathol; 2000 Dec;4(6):367-9
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient who presented with autoimmune hemolytic anemia and small bowel obstruction secondary to a malignant stromal tumor (leiomyosarcoma) of the jejunum, 25 years postchemotherapy and radiation treatment for stage IIA Hodgkin's disease.
  • The patient was treated with corticosteroid therapy and surgical resection of the jejunal tumor.
  • We conclude that autoimmune hemolytic anemia may be an unusual presentation for postirradiation sarcoma.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / etiology. Intestinal Obstruction / etiology. Intestine, Small / pathology. Jejunal Neoplasms / etiology. Leiomyosarcoma / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Male. Middle Aged. Prednisone / therapeutic use. Radiotherapy / adverse effects


26. Kumar B, Bommana V, Irani F, Kasmani R, Mian A, Mahajan K: An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma. QJM; 2009 Jul;102(7):491-3
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon cause of small bowel obstruction: isolated primary granulocytic sarcoma.
  • [MeSH-major] Intestinal Obstruction / etiology. Intestine, Small. Sarcoma, Myeloid / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433489.001).
  • [ISSN] 1460-2393
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down






Advertisement